{"prompt": "['Hand-foot syndrom', 'Grade 2', '- Reduction of 25% of continuous 5-FU', '- No modification', 'Grade 3', '- Bolus reduction of 50%, reduction of 50% of', '- No modification', 'continuous 5-FU', 'Non hematological toxicities', 'Grade 3', '- Bolus reduction of 25% and 25% of continuous', '- Reduction de 25%', '5-FU', 'Grade 4', '- Discuss discontinuation of chemotherapy or only', '- Discuss discontinuation of', 'irinotecan if recurrence despite dose reduction', 'chemotherapy if recurrence despite dose', 'reduction', '7.5. Management of Immune-mediated adverse event (imAE)', 'Guidelines for the management of immune-mediated reactions, infusion-related reactions, and non-immune-', 'mediated reactions for durvalumab are provided in the durvalumab/tremelimumab Toxicity Management', 'Guidelines (TMGs).', 'Patients should be thoroughly evaluated and appropriate efforts should be made to rule out neoplasic, infectious,', 'metabolic, toxin or other etiologic causes of the imAE. Serologic, immunologic and histologic (biopsy) data, as', 'appropriate, should be used to support an imAE diagnosis. In the absence of a clear alternative etiology, events', 'should be considered potentially immune related.', 'All toxicities will be graded according to NCI CTCAE, Version 4.', 'The investigators must make every effort to differentiate chemotherapy-related side effects from those due to', 'immunotherapy. Diarrhea/digestive toxicities could be related to 5-FU, irinotecan, durvalumab and/or', 'tremelimumab. Then urgent GI consult and imaging and/or colonoscopy is required, as appropriate, since', 'treatment will be different according to the drug involved in gastrointestinal toxicity. The characteristics of side', 'effects can differentiate those due to immunotherapy from those due to chemotherapy. Diarrhea/digestive', 'toxicities due to chemotherapy (5-FU and/or irinotecan) usually appear a few days after chemotherapy, with', 'quick improvement with anti-diarrhea treatment.', 'By contrast, diarrhea/digestive toxicities due to immunotherapy usually appear weeks after immunotherapy', 'initiation, with low efficacy of anti-diarrhea treatment. In most cases a colonoscopy with biopsies is needed to', 'differentiate both and used appropriate treatment (immunotherapy stop and at least prednisone 1 to 2 mg/kg/day', 'PO or IV equivalent). Most others toxicities are specific of immunotherapy and never related to chemotherapy', '(pulmonary, endocrine, hepatic imAEs... ).', 'Main toxicities are listed hereinafter. Please refers also to the Toxicity Management guidelines provided', 'appendix 8 of the protocol, if patients have other imAEs. Each updated version of the Toxicity', 'Management Guidelines will be also provided by the sponsor.', 'Gastrointestinal imAEs', 'Severity of Diarrhea/Colitis', 'v4)', 'Management', 'Follow-up', 'Grade 1', 'No dose modifications.', 'Monitor closely for worsening symptoms.', 'Consider symptomatic (e.g.', 'Diarrhea: <4 over baseline', 'loperamide).', 'per day', 'Colitis: asymptomatic', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 26 de 123']['Grade 2', 'Hold Durvalumab or', 'Consider symptomatic treatment, including hydration,', 'Diarrhea: 4 to 6 over baseline', 'Durvalumab/Tremelimumab', 'electrolyte replacement, dietary changes (e.g., American', 'per day', 'regimen until resolution to Grade', 'Dietetic Association colitis diet), and loperamide and/or', '1', 'budesonide.', 'Colitis: abdominal pain;', 'mucus or blood in stool', 'If toxicity worsens, then treat', 'Promptly start prednisone 1 to 2 mg/kg/day PO or IV', 'as Grade 3 or Grade 4.', 'equivalent.', 'If toxicity improves to Grade 1,', 'If event is not responsive within 3 to 5 days or worsens', 'then Durvalumab or', 'despite prednisone at 1 to 2 mg/kg/day PO or IV', 'Durvalumab/Tremelimumab', 'equivalent, GI consult should be obtained for', 'regimen can be resumed after', 'consideration of further workup, such as imaging and/or', 'completion of steroid taper.', 'colonoscopy, to confirm colitis and rule out perforation,', 'and prompt treatment with IV methylprednisolone 2 to 4', 'mg/kg/day started.', 'If still no improvement within 3 to 5 days despite 2 to 4', 'mg/kg IV methylprednisolone, promptly start', 'immunosuppressives such as infliximab at 5 mg/kg once', 'every 2 weeks Caution: it is important to rule out bowel', 'perforation and refer to infliximab label for general', 'guidance before using infliximab.', 'Consider, as necessary, discussing with study physician if', 'no resolution to Grade 1 in 3 to 4 days.', 'Once the patient is improving, gradually taper steroids', 'over >28 days and consider prophylactic antibiotics,', 'antifungals and anti-pneumocystis jiroveci Pneumonia', 'treatment (refer to current NCCN guidelines for treatment', 'of cancer-related infections [Category 2B', 'recommendation]).', 'Grade 3 to 4', 'Grade 3', 'Promptly initiate empiric IV methylprednisolone 2 to', 'Diarrhea (Grade 3): >7 over', 'Permanently discontinue study', '4 mg/kg/day or equivalent.', 'baseline per day', 'drug/study regimen for Grade 3 if', 'Monitor stool frequency and volume and maintain', 'Colitis (Grade 3): severe', 'toxicity does not improve to', 'hydration.', 'abdominal pain, change in', 'Grade <1 within 14 days; study', 'bowel habits, medical', 'drug/study regimen can be', 'Urgent GI consult and imaging and/or colonoscopy as', 'resumed after completion of', 'appropriate.', 'intervention indicated,', 'peritoneal signs', 'steroid taper.', 'If still no improvement within 3 to 5 days of IV', 'methylprednisolone 2 to 4 mg/kg/day or equivalent,', 'Grade 4 diarrhea: life', 'promptly start further immunosuppressives (e.g.,', 'threatening consequences', 'Grade 4', 'infliximab at 5 mg/kg once every 2 weeks). Caution:', 'Permanently discontinue', 'Ensure GI consult to rule out bowel perforation and refer', 'study drug/study regimen.', 'to infliximab label for general guidance before using', 'infliximab.', 'Once the patient is improving, gradually taper steroids', 'over >28 days and consider prophylactic antibiotics,', 'antifungals, and anti-PJP treatment (refer to current', 'NCCN guidelines for treatment of cancer-related', 'infections [Category 2B recommendation].', 'asco Educational Book 2015 \"Managing Immune Checkpoint Blocking Antibody Side Effects\" by Michael Postow MD.', 'Dermatologic imAEs', 'Grade of Rash', '(NCI-CTCAE v4)', 'Management', 'Follow-up', 'General Guidance', 'Any Grade', 'For Any Grade :', '-', '(refer to NCI CTCAE v 4 for', 'Monitor for signs and symptoms of dermatitis', 'definition of severity/grade', '(rash and pruritus).', 'depending on type of skin', 'IF THERE IS ANY BULLOUS FORMATION, THE', 'rash)', 'STUDY PHYSICIAN SHOULD BE CONTACTED', 'AND STUDY DRUG DISCONTINUED.', 'Grade 1', 'No dose modifications.', 'For Grade 1:', 'Covering < 10% body', 'Consider symptomatic treatment, including oral', 'surface area', 'antipruritics (e.g., diphenhydramine or hydroxyzine)', 'and topical therapy (e.g., urea cream).', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 27 de 123']\n\n###\n\n", "completion": "END"}